Efpeglenatide
AMPLITUDE-S
Sanofi · Phase 3 · Terminated · Enrollment 312
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| Efpeglenatide 2 mg | n/r | n/r | n/r | n/r |
| Efpeglenatide 4 mg | n/r | n/r | n/r | n/r |
| Efpeglenatide 6 mg | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- Efpeglenatide 2 mg: endpoint not reported
- Efpeglenatide 4 mg: endpoint not reported
- Efpeglenatide 6 mg: endpoint not reported